NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Lin SY, Azar A, Suarez-Cuervo C, et al. The Role of Immunotherapy in the Treatment of Asthma [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Mar. (AHRQ Comparative Effectiveness Reviews, No. 196.)
- 1.
- Garcia-Robaina JC, Sanchez I, de la Torre F, et al. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol. 2006 Nov;118(5):1026-32. doi: 10.1016/j.jaci.2006.07.043. PMID: 17088125. [PubMed: 17088125] [CrossRef]
- 2.
- Gallego MT, Iraola V, Himly M, et al. Depigmented and polymerised house dust mite allergoid: allergen content, induction of IgG4 and clinical response. Int Arch Allergy Immunol. 2010;153(1):61-9. doi: 10.1159/000301580. PMID: 20357486. [PubMed: 20357486] [CrossRef]
- 3.
- Bousquet J, Calvayrac P, Guerin B, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol. 1985 Nov;76(5):734-44. PMID: 4056259. [PubMed: 4056259]
- 4.
- Ameal A, Vega-Chicote JM, Fernandez S, et al. Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy. 2005 Sep;60(9):1178-83. doi: 10.1111/j.1398-9995.2005.00862.x. PMID: 16076305. [PubMed: 16076305] [CrossRef]
- 5.
- Vidal C, Tabar AI, Figueroa J, et al. Assessment of short-term changes induced by a Dermatophagoides pteronyssinus extract on asthmatic patients. Randomised, double-blind, placebo-controlled trial. Curr Drug Deliv. 2011 Mar;8(2):152-8. PMID: 21235477. [PubMed: 21235477]
- 6.
- Olsen OT, Larsen KR, Jacobsan L, et al. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy. 1997 Aug;52(8):853-9. PMID: 9284985. [PubMed: 9284985]
- 7.
- Kohno Y, Minoguchi K, Oda N, et al. Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma. J Allergy Clin Immunol. 1998 Dec;102(6 Pt 1):927-34. PMID: 9847433. [PubMed: 9847433]
- 8.
- Chakraborty P, Roy I, Chatterjee S, et al. Phoenix sylvestris Roxb pollen allergy: a 2-year randomized controlled trial and follow-up study of immunotherapy in patients with seasonal allergy in an agricultural area of West Bengal, India. J Investig Allergol Clin Immunol. 2006;16(6):377-84. PMID: 17153886. [PubMed: 17153886]
- 9.
- Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Engl J Med. 1996 Feb 22;334(8):501-6. doi: 10.1056/nejm199602223340804. PMID: 8559203. [PubMed: 8559203] [CrossRef]
- 10.
- Ohman JL, Jr., Findlay SR, Leitermann KM. Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses. J Allergy Clin Immunol. 1984 Sep;74(3 Pt 1):230-9. PMID: 6206105. [PubMed: 6206105]
- 11.
- Van Metre TE, Jr., Marsh DG, Adkinson NF, Jr., et al. Immunotherapy for cat asthma. J Allergy Clin Immunol. 1988 Dec;82(6):1055-68. PMID: 2462581. [PubMed: 2462581]
- 12.
- Garcia-Ortega P, Merelo A, Marrugat J, et al. Decrease of skin and bronchial sensitization following short-intensive scheduled immunotherapy in mite-allergic asthma. Chest. 1993 Jan;103(1):183-7. PMID: 8417875. [PubMed: 8417875]
- 13.
- Blumberga G, Groes L, Dahl R. SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma. Allergy. 2011 Feb;66(2):178-85. doi: 10.1111/j.1398-9995.2010.02451.x. PMID: 20883456. [PMC free article: PMC3039748] [PubMed: 20883456] [CrossRef]
- 14.
- Blumberga G, Groes L, Haugaard L, et al. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy. 2006 Jul;61(7):843-8. doi: 10.1111/j.1398-9995.2006.01088.x. PMID: 16792582. [PubMed: 16792582] [CrossRef]
- 15.
- Wang H, Lin X, Hao C, et al. A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy. 2006 Feb;61(2):191-7. doi: 10.1111/j.1398-9995.2005.00913.x. PMID: 16409195. [PubMed: 16409195] [CrossRef]
- 16.
- Maestrelli P, Zanolla L, Pozzan M, et al. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J Allergy Clin Immunol. 2004 Apr;113(4):643-9. doi: 10.1016/j.jaci.2003.12.586. PMID: 15100667. [PubMed: 15100667] [CrossRef]
- 17.
- Ibero M, Castillo MJ. Significant improvement of specific bronchial hyperreactivity in asthmatic children after 4 months of treatment with a modified extract of dermatophagoides pteronyssinus. J Investig Allergol Clin Immunol. 2006;16(3):194-202. PMID: 16784014. [PubMed: 16784014]
- 18.
- Van Bever HP, Stevens WJ. Effect of hyposensitization upon the immediate and late asthmatic reaction and upon histamine reactivity in patients allergic to house dust mite (Dermatophagoides pteronyssinus). Eur Respir J. 1992 Mar;5(3):318-22. PMID: 1572445. [PubMed: 1572445]
- 19.
- Altintas D, Akmanlar N, Guneser S, et al. Comparison between the use of adsorbed and aqueous immunotherapy material in Dermatophagoides pteronyssinus sensitive asthmatic children. Allergol Immunopathol (Madr). 1999 Nov-Dec;27(6):309-17. PMID: 10611556. [PubMed: 10611556]
- 20.
- Hill DJ, Hosking CS, Shelton MJ, et al. Failure of hyposensitisation in treatment of children with grass-pollen asthma. Br Med J (Clin Res Ed). 1982 Jan 30;284(6312):306-9. PMID: 6800440. [PMC free article: PMC1495893] [PubMed: 6800440]
- 21.
- Valovirta E, Koivikko A, Vanto T, et al. Immunotherapy in allergy to dog: a double-blind clinical study. Ann Allergy. 1984 Jul;53(1):85-8. PMID: 6742528. [PubMed: 6742528]
- 22.
- Valovirta E, Jacobsen L, Ljorring C, et al. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy. 2006 Oct;61(10):1177-83. doi: 10.1111/j.1398-9995.2006.01190.x. PMID: 16942565. [PubMed: 16942565] [CrossRef]
- 23.
- Bousquet J, Hejjaoui A, Clauzel AM, et al. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol. 1988 Dec;82(6):971-7. PMID: 3204255. [PubMed: 3204255]
- 24.
- Baris S, Kiykim A, Ozen A, et al. Vitamin D as an adjunct to subcutaneous allergen immunotherapy in asthmatic children sensitized to house dust mite. Allergy. 2014 Feb;69(2):246-53. doi: 10.1111/all.12278. PMID: 24180595. [PubMed: 24180595] [CrossRef]
- 25.
- Kilic M, Altintas DU, Yilmaz M, et al. Evaluation of efficacy of immunotherapy in children with asthma monosensitized to Alternaria. Turk J Pediatr. 2011 May-Jun;53(3):285-94. PMID: 21980810. [PubMed: 21980810]
- 26.
- Lozano J, Cruz MJ, Piquer M, et al. Assessing the efficacy of immunotherapy with a glutaraldehyde-modified house dust mite extract in children by monitoring changes in clinical parameters and inflammatory markers in exhaled breath. Int Arch Allergy Immunol. 2014;165(2):140-7. doi: 10.1159/000368832. PMID: 25471080. [PubMed: 25471080] [CrossRef]
- 27.
- Zielen S, Kardos P, Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol. 2010 Nov;126(5):942-9. doi: 10.1016/j.jaci.2010.06.002. PMID: 20624650. [PubMed: 20624650] [CrossRef]
- 28.
- Pifferi M, Baldini G, Marrazzini G, et al. Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study. Allergy. 2002 Sep;57(9):785-90. PMID: 12169173. [PubMed: 12169173]
- 29.
- Dreborg S, Agrell B, Foucard T, et al. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results. Allergy. 1986 Feb;41(2):131-40. PMID: 3518526. [PubMed: 3518526]
- 30.
- Hui Y, Li L, Qian J, et al. Efficacy analysis of three-year subcutaneous SQ-standardized specific immunotherapy in house dust mite-allergic children with asthma. Exp Ther Med. 2014 Mar;7(3):630-4. doi: 10.3892/etm.2014.1469. PMID: 24520258. [PMC free article: PMC3919950] [PubMed: 24520258] [CrossRef]
- 31.
- Arroabarren E, Tabar AI, Echechipia S, et al. Optimal duration of allergen immunotherapy in children with dust mite respiratory allergy. Pediatr Allergy Immunol. 2015 Feb;26(1):34-41. doi: 10.1111/pai.12296. PMID: 25378059. [PubMed: 25378059] [CrossRef]
- 32.
- Adkinson NF, Jr., Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med. 1997 Jan 30;336(5):324-31. doi: 10.1056/nejm199701303360502. PMID: 9011784. [PubMed: 9011784] [CrossRef]
- 33.
- Limb SL, Brown KC, Wood RA, et al. Long-term immunologic effects of broad-spectrum aeroallergen immunotherapy. Int Arch Allergy Immunol. 2006;140(3):245-51. doi: 10.1159/000093250. PMID: 16691031. [PubMed: 16691031] [CrossRef]
- 34.
- Alzakar RH, Alsamarai AM. Efficacy of immunotherapy for treatment of allergic asthma in children. Allergy Asthma Proc. 2010 Jul-Aug;31(4):324-30. doi: 10.2500/aap.2010.31.3353. PMID: 20819323. [PubMed: 20819323] [CrossRef]
- 35.
- Tsai TC, Lu JH, Chen SJ, et al. Clinical efficacy of house dust mite-specific immunotherapy in asthmatic children. Pediatr Neonatol. 2010 Feb;51(1):14-8. doi: 10.1016/s1875-9572(10)60004-6. PMID: 20225533. [PubMed: 20225533] [CrossRef]
- 36.
- Tsai YG, Chien JW, Chen WL, et al. Induced apoptosis of TH2 lymphocytes in asthmatic children treated with Dermatophagoides pteronyssinus immunotherapy. Pediatr Allergy Immunol. 2005 Nov;16(7):602-8. doi: 10.1111/j.1399-3038.2005.00313.x. PMID: 16238586. [PubMed: 16238586] [CrossRef]
- 37.
- Casanovas M, Sastre J, Fernandez-Nieto M, et al. Double-blind study of tolerability and antibody production of unmodified and chemically modified allergen vaccines of Phleum pratense. Clin Exp Allergy. 2005 Oct;35(10):1377-83. doi: 10.1111/j.1365-2222.2005.02343.x. PMID: 16238799. [PubMed: 16238799] [CrossRef]
- 38.
- Schubert R, Eickmeier O, Garn H, et al. Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy. Int Arch Allergy Immunol. 2009;148(3):251-60. doi: 10.1159/000161585. PMID: 18849616. [PubMed: 18849616] [CrossRef]
- 39.
- Roberts G, Hurley C, Turcanu V, et al. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol. 2006 Feb;117(2):263-8. doi: 10.1016/j.jaci.2005.09.054. PMID: 16461125. [PubMed: 16461125] [CrossRef]
- 40.
- Quiralte J, Justicia JL, Cardona V, et al. Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy. Immunotherapy. 2013 Dec;5(12):1295-303. doi: 10.2217/imt.13.133. PMID: 24283840. [PubMed: 24283840] [CrossRef]
- 41.
- Rank MA, Oslie CL, Krogman JL, et al. Allergen immunotherapy safety: characterizing systemic reactions and identifying risk factors. Allergy Asthma Proc. 2008 Jul-Aug;29(4):400-5. doi: 10.2500/aap.2008.29.3141. PMID: 18702889. [PubMed: 18702889] [CrossRef]
- 42.
- Rank MA, Bernstein DI. Improving the safety of immunotherapy. J Allergy Clin Immunol Pract. 2014 Mar-Apr;2(2):131-5. doi: 10.1016/j.jaip.2013.09.017. PMID: 24607038. [PubMed: 24607038] [CrossRef]
- 43.
- Sana A, Ben Salem C, Ahmed K, et al. Allergen specific immunotherapy induced multi-organ failure. Pan Afr Med J. 2013;14:155. doi: 10.11604/pamj.2013.14.155.1891. PMID: 23785560. [PMC free article: PMC3683521] [PubMed: 23785560] [CrossRef]
- 44.
- Kim ME, Kim JE, Sung JM, et al. Safety of accelerated schedules of subcutaneous allergen immunotherapy with house dust mite extract in patients with atopic dermatitis. J Korean Med Sci. 2011 Sep;26(9):1159-64. doi: 10.3346/jkms.2011.26.9.1159. PMID: 21935270. [PMC free article: PMC3172652] [PubMed: 21935270] [CrossRef]
- 45.
- Sanchez-Morillas L, Reano Martos M, Iglesias Cadarso A, et al. Vasculitis during immunotherapy treatment in a patient with allergy to Cupressus arizonica. Allergol Immunopathol (Madr). 2005 Nov-Dec;33(6):333-4. PMID: 16371222. [PubMed: 16371222]
- 46.
- Ozden MG, Kefeli M, Aydin F, et al. Persistent subcutaneous nodules after immunotherapy injections for allergic asthma. J Cutan Pathol. 2009 Jul;36(7):812-4. doi: 10.1111/j.1600-0560.2008.01152.x. PMID: 19519616. [PubMed: 19519616] [CrossRef]
- 47.
- Gozde Kanmaz H, Harmanci K, Razi C, et al. Specific immunotherapy improves asthma related quality of life in childhood. Allergol Immunopathol (Madr). 2011 Mar-Apr;39(2):68-72. doi: 10.1016/j.aller.2010.04.005. PMID: 20888114. [PubMed: 20888114] [CrossRef]
- 48.
- Kartal O, Gulec M, Caliskaner Z, et al. Safety of subcutaneous immunotherapy with inhalant allergen extracts: a single-center 30-year experience from Turkey. Immunopharmacol Immunotoxicol. 2015 Jun;37(3):280-6. doi: 10.3109/08923973.2015.1027918. PMID: 25858053. [PubMed: 25858053] [CrossRef]
- 49.
- Copenhaver CC, Parker A, Patch S. Systemic reactions with aeroallergen cluster immunotherapy in a clinical practice. Ann Allergy Asthma Immunol. 2011 Nov;107(5):441-7. doi: 10.1016/j.anai.2011.06.026. PMID: 22018617. [PubMed: 22018617] [CrossRef]
- 50.
- Confino-Cohen R, Goldberg A. Allergen immunotherapy-induced biphasic systemic reactions: incidence, characteristics, and outcome: a prospective study. Ann Allergy Asthma Immunol. 2010 Jan;104(1):73-8. doi: 10.1016/j.anai.2009.11.001. PMID: 20143649. [PubMed: 20143649] [CrossRef]
- 51.
- Smits WL, Giese JK, Letz KL, et al. Safety of rush immunotherapy using a modified schedule: a cumulative experience of 893 patients receiving multiple aeroallergens. Allergy Asthma Proc. 2007 May-Jun;28(3):305-12. PMID: 17619559. [PubMed: 17619559]
- 52.
- Chen J, Li B, Zhao Y, et al. A prospective multicenter study of systemic reactions in standardized specific immunotherapy for allergic rhinitis in China. Am J Rhinol Allergy. 2014 Jan-Feb;28(1):e40-4. doi: 10.2500/ajra.2014.28.4005. PMID: 24717880. [PubMed: 24717880] [CrossRef]
- 53.
- Cardona R, Lopez E, Beltran J, et al. Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study. Allergol Immunopathol (Madr). 2014 Mar-Apr;42(2):90-5. doi: 10.1016/j.aller.2012.07.005. PMID: 23265265. [PubMed: 23265265] [CrossRef]
- 54.
- Santos N, Pereira AM, Silva R, et al. Characterisation of systemic reactions to subcutaneous immunotherapy with airborne allergens and classification according to WAO 2010. Allergol Immunopathol (Madr). 2015 Jan-Feb;43(1):25-31. doi: 10.1016/j.aller.2013.10.006. PMID: 24661594. [PubMed: 24661594] [CrossRef]
- 55.
- Eng PA, Borer-Reinhold M, Heijnen IA, et al. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy. 2006 Feb;61(2):198-201. doi: 10.1111/j.1398-9995.2006.01011.x. PMID: 16409196. [PubMed: 16409196] [CrossRef]
- 56.
- Dong X, Huang N, Li W, et al. Systemic Reactions to Dust Mite Subcutaneous Immunotherapy: A 3-Year Follow-up Study. Allergy Asthma Immunol Res. 2016 Sep;8(5):421-7. doi: 10.4168/aair.2016.8.5.421. PMID: 27334780. [PMC free article: PMC4921696] [PubMed: 27334780] [CrossRef]
- 57.
- Lim CE, Sison CP, Ponda P. Comparison of Pediatric and Adult Systemic Reactions to Subcutaneous Immunotherapy. J Allergy Clin Immunol Pract. 2017 Mar 21 doi: 10.1016/j.jaip.2017.01.014. PMID: 28341172. [PubMed: 28341172] [CrossRef]
- 58.
- Virchow JC, Backer V, Kuna P, et al. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. JAMA. 2016 Apr 26;315(16):1715-25. doi: 10.1001/jama.2016.3964. PMID: 27115376. [PubMed: 27115376] [CrossRef]
- 59.
- de Blay F, Kuna P, Prieto L, et al. SQ HDM SLIT-tablet (ALK) in treatment of asthma--post hoc results from a randomised trial. Respir Med. 2014 Oct;108(10):1430-7. doi: 10.1016/j.rmed.2014.07.017. PMID: 25135744. [PubMed: 25135744] [CrossRef]
- 60.
- Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2014 Sep;134(3):568-75 e7. doi: 10.1016/j.jaci.2014.03.019. PMID: 24797423. [PubMed: 24797423] [CrossRef]
- 61.
- Mosbech H, Canonica GW, Backer V, et al. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. Ann Allergy Asthma Immunol. 2015 Feb;114(2):134-40. doi: 10.1016/j.anai.2014.11.015. PMID: 25624131. [PubMed: 25624131] [CrossRef]
- 62.
- Maloney J, Prenner BM, Bernstein DI, et al. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites. Ann Allergy Asthma Immunol. 2016 Jan;116(1):59-65. doi: 10.1016/j.anai.2015.10.024. PMID: 26553448. [PubMed: 26553448] [CrossRef]
- 63.
- Devillier P, Fadel R, de Beaumont O. House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial. Allergy. 2016 Feb;71(2):249-57. doi: 10.1111/all.12791. PMID: 26465232. [PubMed: 26465232] [CrossRef]
- 64.
- Wang L, Yin J, Fadel R, et al. House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. Allergy. 2014 Sep;69(9):1181-8. doi: 10.1111/all.12188. PMID: 25056584. [PubMed: 25056584] [CrossRef]
- 65.
- Gómez VJ, Flores SG, Orea SM, et al. Safety and efficacy of specific sublingual immunotherapy in patients with asthma and allergy to Dermatophagoides pteronyssinus. Revista alergia Mexico (Tecamachalco, Puebla, Mexico: 1993). 2004;52(6):231-6. [PubMed: 16568708]
- 66.
- Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy. 2006 Feb;61(2):185-90. doi: 10.1111/j.1398-9995.2005.00949.x. PMID: 16409194. [PubMed: 16409194] [CrossRef]
- 67.
- Calderon M, Essendrop M. Specific immunotherapy with high dose SO standardized grass allergen tablets was safe and well tolerated. J Investig Allergol Clin Immunol. 2006;16(6):338-44. PMID: 17153880. [PubMed: 17153880]
- 68.
- Marogna M, Braidi C, Bruno ME, et al. The contribution of sublingual immunotherapy to the achievement of control in birch-related mild persistent asthma: a real-life randomised trial. Allergol Immunopathol (Madr). 2013 Jul-Aug;41(4):216-24. doi: 10.1016/j.aller.2012.07.004. PMID: 23141837. [PubMed: 23141837] [CrossRef]
- 69.
- Voltolini S, Troise C, Incorvaia C, et al. Effectiveness of high dose sublingual immunotherapy to induce a stepdown of seasonal asthma: a pilot study. Curr Med Res Opin. 2010 Jan;26(1):37-40. doi: 10.1185/03007990903431886. PMID: 19895362. [PubMed: 19895362] [CrossRef]
- 70.
- Marogna M, Spadolini I, Massolo A, et al. Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. Ann Allergy Asthma Immunol. 2009 Jan;102(1):69-75. doi: 10.1016/s1081-1206(10)60111-1. PMID: 19205289. [PubMed: 19205289] [CrossRef]
- 71.
- Marogna M, Colombo F, Spadolini I, et al. Randomized open comparison of montelukast and sublingual immunotherapy as add-on treatment in moderate persistent asthma due to birch pollen. J Investig Allergol Clin Immunol. 2010;20(2):146-52. PMID: 20461969. [PubMed: 20461969]
- 72.
- Pham-Thi N, Scheinmann P, Fadel R, et al. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol. 2007 Feb;18(1):47-57. doi: 10.1111/j.1399-3038.2006.00475.x. PMID: 17295799. [PubMed: 17295799] [CrossRef]
- 73.
- Bahceciler NN, Isik U, Barlan IB, et al. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol. 2001 Jul;32(1):49-55. PMID: 11416876. [PubMed: 11416876]
- 74.
- La Grutta S, Arena A, D'Anneo WR, et al. Evaluation of the antiinflammatory and clinical effects of sublingual immunotherapy with carbamylated allergoid in allergic asthma with or without rhinitis. A 12-month perspective randomized, controlled, trial. Eur Ann Allergy Clin Immunol. 2007 Feb;39(2):40-4. PMID: 17441414. [PubMed: 17441414]
- 75.
- Stelmach I, Kaczmarek-Wozniak J, Majak P, et al. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin Exp Allergy. 2009 Mar;39(3):401-8. doi: 10.1111/j.1365-2222.2008.03159.x. PMID: 19134016. [PubMed: 19134016] [CrossRef]
- 76.
- Lue KH, Lin YH, Sun HL, et al. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol. 2006 Sep;17(6):408-15. doi: 10.1111/j.1399-3038.2006.00443.x. PMID: 16925685. [PubMed: 16925685] [CrossRef]
- 77.
- Niu CK, Chen WY, Huang JL, et al. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med. 2006 Aug;100(8):1374-83. doi: 10.1016/j.rmed.2005.11.016. PMID: 16403616. [PubMed: 16403616] [CrossRef]
- 78.
- Ippoliti F, De Santis W, Volterrani A, et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol. 2003 Jun;14(3):216-21. PMID: 12787302. [PubMed: 12787302]
- 79.
- Tian M, Wang Y, Lu Y, et al. Effects of sublingual immunotherapy for Dermatophagoides farinae on Th17 cells and CD4(+) CD25(+) regulatory T cells in peripheral blood of children with allergic asthma. Int Forum Allergy Rhinol. 2014 May;4(5):371-5. doi: 10.1002/alr.21305. PMID: 24591191. [PubMed: 24591191] [CrossRef]
- 80.
- Shao J, Cui YX, Zheng YF, et al. Efficacy and safety of sublingual immunotherapy in children aged 3-13 years with allergic rhinitis. Am J Rhinol Allergy. 2014 Mar-Apr;28(2):131-9. doi: 10.2500/ajra.2014.28.4006. PMID: 24717951. [PubMed: 24717951] [CrossRef]
- 81.
- Corzo JL, Carrillo T, Pedemonte C, et al. Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children. J Investig Allergol Clin Immunol. 2014;24(3):154-61. PMID: 25011352. [PubMed: 25011352]
- 82.
- Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol. 2009 Jan;123(1):167-73 e7. doi: 10.1016/j.jaci.2008.10.044. PMID: 19130937. [PubMed: 19130937] [CrossRef]
- 83.
- Mosges R, Graute V, Christ H, et al. Safety of ultra-rush titration of sublingual immunotherapy in asthmatic children with tree-pollen allergy. Pediatr Allergy Immunol. 2010 Dec;21(8):1135-8. PMID: 21121080. [PubMed: 21121080]
- 84.
- Dunsky EH, Goldstein MF, Dvorin DJ, et al. Anaphylaxis to sublingual immunotherapy. Allergy. 2006 Oct;61(10):1235. doi: 10.1111/j.1398-9995.2006.01137.x. PMID: 16942576. [PubMed: 16942576] [CrossRef]
- 85.
- Vovolis V, Kalogiros L, Mitsias D, et al. Severe repeated anaphylactic reactions to sublingual immunotherapy. Allergol Immunopathol (Madr). 2013 Jul-Aug;41(4):279-81. doi: 10.1016/j.aller.2012.05.012. PMID: 23253689. [PubMed: 23253689] [CrossRef]
- 86.
- Ventura MT, D'Erasmo M, di Gioia R, et al. Adverse reaction to specific immunotherapy for house-dust mite in a patient with Anisakis allergy. J Eur Acad Dermatol Venereol. 2008 Feb;22(2):259-60. doi: 10.1111/j.1468-3083.2007.02312.x. PMID: 18211437. [PubMed: 18211437] [CrossRef]
- 87.
- Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy. 2008 Mar;63(3):374. doi: 10.1111/j.1398-9995.2007.01563.x. PMID: 18076729. [PubMed: 18076729] [CrossRef]
- 88.
- Moral A, Moreno V, Girón F, et al. Adverse reactions and tolerability of high-dose sublingual allergen immunotherapy. Journal of Asthma and Allergy. 2016;9:129. [PMC free article: PMC4935085] [PubMed: 27418842]
- 89.
- Roger A, Justicia JL, Navarro LA, et al. Observational study of the safety of an ultra-rush sublingual immunotherapy regimen to treat rhinitis due to house dust mites. Int Arch Allergy Immunol. 2011;154(1):69-75. doi: 10.1159/000319211. PMID: 20664280. [PubMed: 20664280] [CrossRef]
- 90.
- De Castro G, Zicari AM, Indinnimeo L, et al. Efficacy of sublingual specific immunotherapy on allergic asthma and rhinitis in children's real life. Eur Rev Med Pharmacol Sci. 2013 Aug;17(16):2225-31. PMID: 23893190. [PubMed: 23893190]
- 91.
- Nuhoglu Y, Ozumut SS, Ozdemir C, et al. Sublingual immunotherapy to house dust mite in pediatric patients with allergic rhinitis and asthma: a retrospective analysis of clinical course over a 3-year follow-up period. J Investig Allergol Clin Immunol. 2007;17(6):375-8. PMID: 18088019. [PubMed: 18088019]
- 92.
- Galip N, Bahceciler N. Rare adverse events due to house dust mite sublingual immunotherapy in pediatric practice: two case reports. Immunotherapy. 2015;7(12):1235-9. doi: 10.2217/imt.15.88. PMID: 26427747. [PubMed: 26427747] [CrossRef]
- 93.
- Béné J, Ley D, Roboubi R, et al. Eosinophilic esophagitis after desensitization to dust mites with sublingual immunotherapy. Annals of Allergy, Asthma & Immunology. 2016;116(6):583-4. [PubMed: 27067457]
- 94.
- Mungan D, Misirligil Z, Gurbuz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study. Ann Allergy Asthma Immunol. 1999 May;82(5):485-90. doi: 10.1016/s1081-1206(10)62726-3. PMID: 10353581. [PubMed: 10353581] [CrossRef]
- 95.
- Li H, Yang P, Chen X, et al. A comparative study of sublingual and subcutaneous immunotherapy in mite-sensitive asthmatic children: A single center experience of 90 Chinese patients. International Journal of Clinical and Experimental Medicine. 2016;9(3):6743-50.
- 96.
- Yukselen A, Kendirli SG, Yilmaz M, et al. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol. 2012;157(3):288-98. doi: 10.1159/000327566. PMID: 22041501. [PubMed: 22041501] [CrossRef]
- 97.
- Yukselen A, Kendirli SG, Yilmaz M, et al. Two year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing subcutaneous and sublingual immunotherapy. Asian Pac J Allergy Immunol. 2013 Sep;31(3):233-41. doi: 10.12932/ap0276.31.3.2013. PMID: 24053706. [PubMed: 24053706] [CrossRef]
- 98.
- Keles S, Karakoc-Aydiner E, Ozen A, et al. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes. J Allergy Clin Immunol. 2011 Oct;128(4):808-15 e7. doi: 10.1016/j.jaci.2011.04.033. PMID: 21641635. [PubMed: 21641635] [CrossRef]
- 99.
- Karakoc-Aydiner E, Eifan AO, Baris S, et al. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial. J Investig Allergol Clin Immunol. 2015;25(5):334-42. PMID: 26727762. [PubMed: 26727762]
- 100.
- Eifan AO, Akkoc T, Yildiz A, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy. 2010 Jun;40(6):922-32. doi: 10.1111/j.1365-2222.2009.03448.x. PMID: 20100188. [PubMed: 20100188] [CrossRef]
- 101.
- Cochard MM, Eigenmann PA. Sublingual immunotherapy is not always a safe alternative to subcutaneous immunotherapy. J Allergy Clin Immunol. 2009 Aug;124(2):378-9. doi: 10.1016/j.jaci.2009.04.040. PMID: 19541352. [PubMed: 19541352] [CrossRef]
- 102.
- Garde J, Ferrer A, Jover V, et al. Tolerance of a Salsola kali extract standardized in biological units administered by subcutaneous route. Multicenter study. Allergol Immunopathol (Madr). 2005 Mar-Apr;33(2):100-4. PMID: 15808117. [PubMed: 15808117]
- References - The Role of Immunotherapy in the Treatment of AsthmaReferences - The Role of Immunotherapy in the Treatment of Asthma
- Risk of Bias Assessment - The Role of Immunotherapy in the Treatment of AsthmaRisk of Bias Assessment - The Role of Immunotherapy in the Treatment of Asthma
- Acknowledgments - PCA3 Testing for the Diagnosis and Management of Prostate Canc...Acknowledgments - PCA3 Testing for the Diagnosis and Management of Prostate Cancer
- Characteristics of Key Question 1 and 2 Studies - Impact of Healthcare Algorithm...Characteristics of Key Question 1 and 2 Studies - Impact of Healthcare Algorithms on Racial and Ethnic Disparities in Health and Healthcare
- Exact Search Strings - Interventions To Improve Cardiovascular Risk Factors in P...Exact Search Strings - Interventions To Improve Cardiovascular Risk Factors in People With Serious Mental Illness
Your browsing activity is empty.
Activity recording is turned off.
See more...